Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.
Screened 2026-07-19 · the tape above runs as of 22:26 UTC · 7 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Apellis Pharmaceuticals, Inc. holds its Accumulation at $41.03. Elevated stress, defensive posture warranted, held for 12 days.
As held on the ledger · 2026-07-19
Phase
Accumulation
Quantitative state
Elevated stress, defensive posture warranted, held for 12 days
Price at the screen
$41.03
Valuation
38.35 trailing · -130.55 forward price to earnings
Values screen
PASS· score 93.6
Beta
-0.25
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
9.06%
Below 33%
Interest-bearing debt is just 9.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
7.73%
Below 33%
Cash held in interest-bearing accounts and securities is 7.7% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads FAIR VALUE: it trades above our $41.00 fair value estimate, 60.90% revenue growth.
Fair value range in USD, drawn from the 2026-07-19 screen. The gold marker is the market price at the same screen. The price runs 0.1% above the base estimate.
Third-party analyst targets: 13 covering, consensus Hold. The average target sits −0% from the screen price.
Reading the gap · Our model and the Street both land near today's price: fairly valued, with no strong edge either way.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-07-19 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech firm priced exactly at fair value
Picture a commercial-stage drug maker finally turning high unmet needs into real sales. Apellis has delivered 61% revenue growth and a 12% profit margin while posting a striking 46% return on equity. Those numbers explain why the shares sit right at our calculated fair value with zero margin of safety.
The business clears our ethical screen and the analyst consensus lines up with a hold rating and a median target matching the current price. Forward earnings are still negative, however, so the strong recent profitability has yet to translate into sustained positive forecasts.
Risk sits in the usual biotech uncertainties around future trial outcomes and reimbursement, plus the fact that a negative forward multiple leaves little room for disappointment. The market is not offering a bargain or a clear overvaluation at these levels. Analysis, not advice.
APLS trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-21Accumulation$41.03+0.0%Entry 6
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 57% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 151%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it hold, with a mean price target of $41.
2026-07-21Accumulation$41.03+0.0%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 57% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 151%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it hold, with a mean price target of $41.
2026-07-18Accumulation$41.03+0.0%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 57% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 151%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it hold, with a mean price target of $41.
2026-07-17Accumulation$41.03+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (94). The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 57% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 151%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it hold, with a mean price target of $41.
2026-07-03Accumulation$41.03+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (94). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Accumulation$41.03Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with near-perfect ethical score (94). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
